Related Experiment Video
Updated: May 4, 2026
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
Published on: December 3, 2020
[Role of CD47 in hematologic malignancies]
1The Second Department of Hematology, Cangzhou Central Hospital, Cangzhou 061000, Hebei Province, China.
Insights
CD47, a cell surface protein, interacts with SIRPα to regulate immune responses. This interaction is crucial in hematologic diseases and offers potential therapeutic strategies for cancer and transplantation.
Area of Science:
- Immunology
- Oncology
- Hematology
Background:
- CD47 is a ubiquitous transmembrane glycoprotein involved in immune regulation.
- Its interaction with SIRPα on phagocytic cells transmits inhibitory signals.
- CD47-SIRPα signaling impacts inflammatory, immune, and tumor immunity.
Purpose of the Study:
- To review the structure and immunoregulatory functions of CD47.
- To explore CD47's role in tumor therapy.
- To discuss CD47's involvement in hematologic malignancies and stem cell transplantation.
Main Methods:
- Literature review of CD47's structure and function.
- Analysis of CD47-SIRPα signaling pathways.
- Synthesis of current research on CD47 in hematologic diseases and cancer therapy.
Main Results:
- CD47-SIRPα signaling is a key regulator of immune cell interactions.
- Dysregulation of CD47 contributes to the pathogenesis of hematologic malignancies.
- CD47 blockade is a promising therapeutic approach in oncology and transplantation.
Conclusions:
- CD47 plays a critical role in immune evasion and pathogenesis of hematologic diseases.
- Targeting the CD47-SIRPα axis presents a viable therapeutic strategy.
- Further research is warranted to optimize CD47-based therapies for various conditions.
Abstract:
CD47 is a ubiquitously expressed transmembrane glycoprotein on surface of many cells. Through its interaction with integrin, signal regulatory protein alpha (SIRPα) and thrombin sensitive protein-1 (TSP-1), it plays important roles in various immunological processes including inflammatory response, immune response and tumor immunity. Recently, it has been found that CD47 interacts with SIRPα expressed on phagocytic cells, which transfers a negative signal when being activated. By the mechanisms described above, CD47-SIRPα signal complex is involved in the pathogenesis of hematological diseases and might provide some informations for the therapy of patients. This review focuses on the structure and immunoregulatory functions of CD47, the mechanism of CD47 in tumor therapy, the CD47 and hematologic malignancies including acute leukemia, B-cell lymphoma and multiple myeloma, as well as CD47 and hematopoietic stem cell transplantation.
More Related Videos
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
10:15The Use of the Ex Vivo Chandler Loop Apparatus to Assess the Biocompatibility of Modified Polymeric Blood Conduits
Published on: August 20, 2014
Related Concept Videos
01:01Regulation of Hematopoietic Stem Cells
01:28Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...